KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to -$254000.0.

  • Bionano Genomics' Change in Account Payables fell 71935.48% to -$254000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 5532.51%. This contributed to the annual value of -$3.4 million for FY2024, which is 7142.86% down from last year.
  • As of Q3 2025, Bionano Genomics' Change in Account Payables stood at -$254000.0, which was down 71935.48% from -$318000.0 recorded in Q2 2025.
  • Bionano Genomics' 5-year Change in Account Payables high stood at $4.1 million for Q3 2021, and its period low was -$4.4 million during Q4 2023.
  • Over the past 5 years, Bionano Genomics' median Change in Account Payables value was -$254000.0 (recorded in 2025), while the average stood at $123263.2.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 66911.31% in 2021, then crashed by 71935.48% in 2025.
  • Quarter analysis of 5 years shows Bionano Genomics' Change in Account Payables stood at $1.8 million in 2021, then soared by 73.31% to $3.2 million in 2022, then tumbled by 238.15% to -$4.4 million in 2023, then surged by 60.4% to -$1.7 million in 2024, then soared by 85.41% to -$254000.0 in 2025.
  • Its Change in Account Payables was -$254000.0 in Q3 2025, compared to -$318000.0 in Q2 2025 and -$401000.0 in Q1 2025.